These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 27995810)
1. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810 [TBL] [Abstract][Full Text] [Related]
2. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328 [TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Li N; Wang Y; Deng W; Lin SH Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796 [TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Dulaney C; Marcrom S; Stanley J; Yang ES Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320 [TBL] [Abstract][Full Text] [Related]
5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. Li Y; Liu CF; Rao GW Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505 [TBL] [Abstract][Full Text] [Related]
6. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation. Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983 [TBL] [Abstract][Full Text] [Related]
7. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. Sargazi S; Mukhtar M; Rahdar A; Barani M; Pandey S; Díez-Pascual AM Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638660 [TBL] [Abstract][Full Text] [Related]
8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface? Hottiger MO Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149 [TBL] [Abstract][Full Text] [Related]
11. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942 [No Abstract] [Full Text] [Related]
12. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer. Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786 [TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship. Das PK; Matada GSP; Pal R; Maji L; Dhiwar PS; Manjushree BV; Viji MP Eur J Med Chem; 2024 Aug; 274():116535. PubMed ID: 38838546 [TBL] [Abstract][Full Text] [Related]
14. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. Wang Q; Zhang J Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258 [TBL] [Abstract][Full Text] [Related]
15. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Gunderson CC; Moore KN Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679 [TBL] [Abstract][Full Text] [Related]
16. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Mégnin-Chanet F; Bollet MA; Hall J Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763 [TBL] [Abstract][Full Text] [Related]
17. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy by PARP inhibitors]. Seimiya H Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review. AlGhamdi A; AlMubayedh H Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. Rajawat J; Shukla N; Mishra DP Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]